Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 27;41(13):2234–2242. doi: 10.1016/j.vaccine.2023.02.068

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s)

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 3 — Anti-RBD IgG titers and neutralizing titers 2 and 5 months after two and three doses of mRNA vaccine in SARS-CoV2 naïve participants by age group. (A) SARS-CoV-2 RBD IgG titer. (B) Neutralizing titers against SARS-CoV-2pv. N = 284. ^***, p < 0.001; *, p < 0.05; NS, not significant, using the Jonckheere-Terpstra test. Abbreviations: RBD, receptor-binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SARS-CoV-2pv, severe acute respiratory syndrome coronavirus 2 pseudotyped virus.